New drug trial aims to tame Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase study tests a new drug called Sapu003 in 27 adults with advanced solid tumors (like breast, kidney, or liver cancer) that are sensitive to mTOR-targeted therapy. The main goal is to find the safest dose and check for side effects. Participants receive Sapu003 wee…
Phase: PHASE1 • Sponsor: SAPU NANO (US) LLC • Aim: Disease control
Last updated May 17, 2026 01:48 UTC